JDD Special Focus

Acne Case Reports

Stay up-to-date on new clinical findings on Acne. View the latest articles, case reports, editorial features, supplements, Podcast episodes and more!

 

Case Reports

Efficacy and Safety of Sarecycline, a Novel, Once-Daily, Narrow Spectrum Antibiotic for the Treatment of Moderate to Severe Facial Acne Vulgaris: Results of a Phase 2, Dose-Ranging Study

J Drugs Dermatol. 2018;17(3):333-338.

James J. Leyden MD,a Vilma Sniukiene MD,b David R. Berk MD,b and Alexandre Kaoukhov MDb

There is a need for new oral antibiotics for acne with improved safety profiles and targeted antibacterial spectra. Sarecycline is a novel, tetracycline-class antibiotic specifically designed for acne, offering a narrow spectrum of activity compared with currently available tetracyclines, including less activity against enteric Gram-negative bacteria. This phase 2 study evaluated the efficacy and safety of three doses of sarecycline for moderate to severe facial acne vulgaris.

Sponsored

Podcast Episodes

Ask the Investigator: Acne, OCPs, and a Side Order of Practical Pearls for the Adolescent Patient

JDD Podcast host Dr. Adam Friedman gets first-hand insight from internationally acclaimed pediatric dermatologist Dr. Lawrence Eichenfield on his recent study entitled “Hormonal Contraceptives and Acne: A Retrospective Analysis of 2147 Patients” published in the June 2016 edition of the Journal of Drugs of Dermatology. Want a refresher on the use of OCPs in Acne?

Interested in learning how to initiate a patient based survey study? Just curious how a leader in the field gets an uninterested adolescent to be compliant and engaged in his/her acne care? These are just a few of the practical pearls provided.

Listen Now

Sponsored

Featured Editorials

Virtual Exams No Substitute for In-Person Care of Acne and Rosacea

Some dermatologists may be surprised to hear that the concept of teledermatology originated 25 years ago, and has slowly increased in usage, primarily for the purpose of providing care to those in underserved areas.1 The challenges created by the COVID19 pandemic has rapidly accelerated both interest and usage of telemedicine by dermatologists, with the American Academy of Dermatology and other dedicated groups responding quickly to provide guidance on how to integrate teledermatology into real-world dermatology practice effectively, and hopefully with avoidance of technical, medicolegal, and financial pitfalls.2

 

Read Now

Sponsored

Featured Supplement

Androgens, Androgen Receptors, and the Skin

Of the four primary pathogenic factors that drive acne vulgaris—androgen excess, increased sebum production, faulty keratinization, and overgrowth of C. acnes—androgen excess has been the most elusive therapeutic target. Oral contraceptive pills (OCPs) have direct effect on circulating hormones, but their potential use is limited to a subset of women. As such, a sizable portion of the population affected by acne vulgaris cannot even consider treatment with OCPs. While these systemic agents are generally associated with a low risk profile and have a history of safe and effective use, they are not entirely risk-free. Indirect androgen modulation through the use of spironolactone has become increasingly popular. Again, while generally safe and effective, this systemic treatment is not without risks and contraindications and it is also limited to a subset of female patients.

Read Now

Dermatology News

AcneCME ActivitiesJDD Webinars
April 9, 2021

Actinic Keratosis: Current Understanding of Pathophysiology and Therapeutic Targets

Watch on Demand Now to Earn 1.0 CE Credit!  Earn 1.0 CE Credit: Join JDD for Part One of this two-part webinar series on "Advancing the Understanding of Actinic Keratosis:…
CME ActivitiesPodcast
March 23, 2021

The Science of Sun Protection

Episode 1 of a 2-Part Series: "Sun Protection: A Review of Current Interventions and Barriers to Changing Patient Attitude and Behavior" Photoprotection works, plain and simple. Yet all too often…
What's New in Topical Treatment for Actinic KeratosisCME ActivitiesJDD Webinars
March 18, 2021

What’s New in Topical Treatment for Actinic Keratosis

In this one-hour CME webinar, participants will learn the latest information on new topical therapeutic considerations for actinic keratosis, including the recently approved SrC kinase inhibitor. Watch the Webinar here…
Featured ArticlesHome page featureSkin CancerThe Latest
March 10, 2021

Survey provides insight into factors that influence men’s sunscreen use

While men are more likely than women to develop skin cancer, a recent survey indicates most do not use sunscreen on a daily basis. Heather Onorati While men are more…